Witte C, Martos V, Rose HM, Reinke S, Klippel S, Schroder L, Hackenberger CP. Live-cell MRI with xenon hyper-CEST biosensors targeted to metabolically labeled cell-surface glycans. Angew Chem Int Ed Engl 2015, 54 (9), 2806-10.
Schnurr M, Sloniec-Myszk J, Dopfert J, Schroder L, Hennig A. Supramolecular Assays for Mapping Enzyme Activity by Displacement-Triggered Change in Hyperpolarized (129)Xe Magnetization Transfer NMR Spectroscopy. Angew Chem Int Ed Engl 2015, 54 (45), 13444-7.
Kunth M, Witte C, Hennig A, Schroder L. Identification, classification, and signal amplification capabilities of high-turnover gas binding hosts in ultra-sensitive NMR. Chemical Science 2015, 6 (11), 6069-6075.
Rose HM, Witte C, Rossella F, Klippel S, Freund C, Schroder L. Development of an antibody-based, modular biosensor for 129Xe NMR molecular imaging of cells at nanomolar concentrations. Proceedings of the National Academy of Sciences of the United States of America 2014, 111 (32), 11697-702.
Schröder L, Lowery TJ, Hilty C, Wemmer DE, Pines A. Molecular Imaging Using a Targeted Magnetic Resonance Hyperpolarized Biosensor. Science 2006, 314 (5798), 446-449.
Our group works on the development of novel magnetic resonance reporters and the related detection techniques for diagnostic imaging and spectroscopy. Xenon biosensors have an outstanding potential to increase the significance of magnetic resonance imaging (MRI) in molecular diagnostics. To explore this potential, our group uses the Hyper-CEST method as an ultra-sensitive technique in xenon MRI to combine the advantages of non-invasive imaging with the high sensitivity of hyperpolarized xenon and the specificity of functionalized reporters.
Advancements focus on high-sensitivity in vitro diagnostics for live cell detection of disease markers previously inaccessible for MRI and further translation into animal models. By combining methods from physics, biochemistry and cell biology, we pursue projects on early detection of various pathologies, including different types of cancer and Parkinson's disease. This work aims to close the sensitivity gap between modalities of nuclear medicine like PET/SPECT and MRI without using ionizing radiation or making compromises in penetration depth like in optical methods.